Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
about
MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.Long Non-coding RNA TUSC7, a Target of miR-23b, Plays Tumor-Suppressing Roles in Human Gliomas.Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis.Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.MicroRNA in Glioblastoma: An Overview.Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications.Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.Substituted Caffeic and Ferulic Acid Phenethyl Esters: Synthesis, Leukotrienes Biosynthesis Inhibition, and Cytotoxic Activity.Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes.Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma.Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway.Epigenetic Targeting of GlioblastomaImmune Checkpoints and Innovative Therapies in GlioblastomaInvolvement of NOS2 Activity on Human Glioma Cell Growth, Clonogenic Potential, and Neurosphere Generation
P2860
Q33648875-C71E234A-2DE4-47AC-9DA0-4279FA7784AAQ37314044-3626AD03-C40C-4AC4-B4C3-1303F35C8FCAQ38632886-C1589FC5-B475-46DB-AF83-78D925E98D8BQ38740314-285CF61A-79EC-4D9A-ABF2-80D77062C7C2Q38743138-FABF614E-EE83-404D-8362-F5FD6DDC718EQ39139224-3C5F896B-AD5C-4341-9D6B-35F0512AFFCFQ39417407-91D93765-163C-4E6E-9137-9152AA08FD01Q47142132-32C41A0A-D707-4B9D-854C-FA1BEDDE10C3Q47153393-D8920D45-D9EE-43E1-AD7D-87439B055430Q47748770-725D169C-C5B0-465E-831E-A8082C4C8BB4Q47853442-8B12D660-C93D-4878-B5D1-8E9164A6FC8FQ47894744-A2C699D3-4C63-4B7A-95C8-6267581B89E9Q48009516-94CAB362-0D95-4675-8C19-8110E45C2D14Q48207987-88663518-DE46-4AD5-AD59-4596F461DAE7Q52626675-C2511201-D296-4C5B-8E84-D2A396F4BA50Q52657235-E460F9C3-472F-4AB6-8F29-7E0906BF66A6Q53176029-06BD2031-58C2-44C1-A6DF-4B9EF7B760BAQ58554073-FD30E32E-0F3F-4B8D-B23D-5FA31E39CA4FQ58573409-4B949AAB-A0DF-4535-BEF2-EA6D13723289Q58729699-310FC261-056D-4294-80D5-56023C884478
P2860
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
@en
type
label
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
@en
prefLabel
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
@en
P2093
P2860
P1476
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
@en
P2093
Adam L Cohen
Howard Colman
Ricky Chen
P2860
P2888
P356
10.1007/S11864-016-0418-0
P577
2016-08-01T00:00:00Z
P6179
1009202533